A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

Clinical trial NCT05076149 · COMPLETED

Trial details

NCT number: NCT05076149
Sponsor: Vertex Pharmaceuticals Incorporated
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Cystic Fibrosis

Start date: 2021-10-27
Primary completion: 2023-05-18
Enrollment: 597

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.